Integration of pharmacokinetic and NRF2 system biology models to describe reactive oxygen species production and subsequent glutathione depletion in liver microfluidic biochips after flutamide exposure

Toxicology in Vitro

Volumn 28, Issue 7, 2014, Pages 1230-1241

  Leclerc, Eric ^a   Hamon, Jeremy ^a   Legendre, Audrey ^a   Bois, Frederic Y ^a,b  

^a UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^b INSTITUT NATIONAL DE L ENVIRONNEMENT INDUSTRIEL ET DES RISQUES INERIS   (France)

Author keywords

Flutamide; Hepatocytes; Microfluidic biochips; Nrf2 systems biology modeling; Pharmacokinetic modeling

Indexed keywords

FLUTAMIDE; GLUTATHIONE; HYDROXYFLUTAMIDE; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; ANTIANDROGEN; NFE2L2 PROTEIN, RAT;

ANIMAL CELL; ARTICLE; BIOCHIP; COMPUTER MODEL; CONTROLLED STUDY; DRUG METABOLISM; EXTRACELLULAR FLUID; GENE ACTIVITY; GENE SWITCHING; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR FLUID; LIVER CELL; LIVER NECROSIS; MICROARRAY ANALYSIS; MICROFLUIDICS; NONHUMAN; PROTEIN DEPLETION; RAT; SYSTEMS BIOLOGY; TOXICOKINETICS; TRANSCRIPTOMICS; ANIMAL; BIOLOGICAL MODEL; BIOREACTOR; CELL CULTURE; DRUG EFFECTS; LIVER; METABOLISM;

ANDROGEN ANTAGONISTS; ANIMALS; BIOREACTORS; CELLS, CULTURED; FLUTAMIDE; GLUTATHIONE; HEPATOCYTES; LIVER; MICROFLUIDICS; MODELS, BIOLOGICAL; NF-E2-RELATED FACTOR 2; RATS; REACTIVE OXYGEN SPECIES; SYSTEMS BIOLOGY;

EID: 84904279966     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2014.05.003     Document Type: Article

References (46)

1. Aizawa Y., Ikemoto I., Kishimoto K., Wada T., Yamazaki H., Ohishi Y., Kiyota H., Furuta N., Suzuki H., Ueda M. Flutamide-induced hepatic dysfunction in relation to steady-state plasma concentrations of flutamide and its metabolites. Mol. Cell. Biochem. 2003, 252:149-156.
2. Baudoin R., Prot J.M., Nicolas G., Brocheton J., Brochot C., Legallais C., Benech H., Leclerc E. Evaluation of seven drug metabolisms and clearances by cryopreserved Human primary hepatocytes cultivated in microfluidic biochips. Xenobiotica 2013, 43:140-152.
3. Baudoin R., Legendre A., Jacques S., Cotton J., Bois F., Leclerc E. Evaluation of a liver microfluidic biochip to predict in vivo clearances of seven drugs in rats. J. Pharm. Sci. 2014, 103:706-718.
4. Baudoin R., Alberto G., Legendre A., Paullier P., Naudot M., Fleury M.J., Jacques S., Griscom L., Leclerc E. Investigation of the levels of expression and activity of detoxication genes of primary rat hepatocytes under various flow rates and cell densities in microfluidic biochips. Biotechnol. Prog. 2014, 30:401-410.
5. Bhogal N., Grindon C., Combes R., Balls M. Toxicity testing: creating a revolution based on new technologies. Trends Biotechnol. 2005, 23:299-307.
6. Blaauboer B.J. The integration of data on physico-chemical properties, in vitro-derived toxicity data and physiologically based kinetic and dynamic as modelling a tool in hazard and risk assessment. A commentary. Toxicol. Lett. 2003, 138:161-171.
7. Bois F.Y. GNU MCSIM: Bayesian statistical inference for SBML coded systems biology models. Bioinformatics 2009, 25:1453-1454.
8. Bois F.Y. Baysian inference. Methods Mol. Biol. 2013, 930:597-636.
9. Bouvier d'Yvoire M., Prieto P., Blaauboer B.J., Bois F.Y., Boobis A., Brochot C., Coecke S., Freidig A., Gundert-Remy U., Hartung T., Jacobs M.N., Lavé T., Leahy D.E., Lennernäs H., Loizou G.D., Meek B., Pease C., Rowland M., Spendiff M., Yang J., Zeilmaker M. Physiologically-based kinetic modelling (PBK modelling): meeting the 3Rs agenda. The report and recommendations of ECVAM Workshop 63. Altern. Lab. Anim. 2007, 35:661-671.
10. Brown H., Griffin M., Houston B. Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearances. Drug Metab. Dispos. 2007, 35:293-301.
11. Carlile D., Katayoun Z., Houston B. Scaling factors to related drug metabolic clearance in hepatic microsomes, isolated hepatocytes and the intact liver. Drug Metab. Dispos. 1997, 25:903-911.
12. Chen Y., Shertzer H.G., Schneider S.N., Nebert D.W., Dalton T.P. Glutamate cysteine ligase catalysis: dependence on ATP and modifier subunit for regulation of tissue glutathione levels. J. Biol. Chem. 2005, 280:33766-33774.
13. Choucha Snouber L., Letourneur F., Chafey P., Broussard C., Monge M., Legallais C., Leclerc E. Analysis of transcriptomic and proteomic profiles demonstrates the improvement of the MDCK cell function in a renal microfluidic biochip. Biotechnol. Prog. 2012, 28:474-484.
14. Coe K., Nelson S., Ulrich R., He Y., Dai X., Cheng O., Caguyong M.Roberts C., Slatter G. Profiling the hepatic effects of flutamide in rats: a microarray comparison with classical aryl hydrocarbon receptor ligands and atypical CYP1A inducers. Drug Metab. Dispos. 2006, 34:1266-1275.
15. Coe K., Jiav Y., Ho H., Rademacher P., Bammler T., Beyer R., Farin F., Woodke L., Stephen R., Plymate S., Fausto N., Nelson S. Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screening. Chem. Res. Toxicol. 2007, 20:1277-1290.
16. Esch M., King T., Shuler M. The role of body-on-a-chip devices in drug and toxicity studies. Annu. Rev. Biomed. Eng. 2011, 13:55-72.
17. Fulda S., Gorman A., Hori Osamu, Samali A. Cellular stress response: cell survival and cell death. Int. J. Cell Biol. 2010, 3:1-23.
18. Geenen S., Taylor P., Snoep J., Wilson I., Kenna G., Westerhoff H. Systems biology tools for toxicology. Arch. Toxicol. 2012, 86:1251-1271.
19. Geenen S., Yates J., Kenna G., Bois F., Wilson I., Westerhoff H. Multiscale modelling approach combining a kinetic model of glutathione metabolism with PBPK models of paracetamol and the potential glutathionedepletion biomarkers ophthalmic acid and 5-oxoproline in humans and rats. Integr. Biol. 2013, 5:877-883.
20. Gelman A., Rubin D.B. Inference from iterative simulation using multiple sequences (with discussion). Stat. Sci. 1992, 7:457-511.
21. Gonçalves E., Bucher J., Ryll A., Niklas J., Mauch K., Klamt S., Rocha M., Saez-Rodriguez J. Bridging the layers: towards integration of signal transduction, regulation and metabolism into mathematical models. Mol. BioSyst. 2013, 9:1576.
22. Hakooz N., Ito K., Rawden H., Gill H., Lemmers L., Boobis A.R., Edwards R.J., Carlile D.J., Lake B.G., Houston J.B. Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. Pharm. Res. (NY) 2006, 23:533-539.
23. Hamon, J., Jennings, P., Bois, F.Y. Integration of omics data and systems biology modeling: effect of cyclosporine A on the Nrf2 pathway in human renal kidneys cells, BMC Systems biology, in press.
24. Ierapetritou M., Georgopoulos P., Roth C., Androulakis I. Tissue-level modeling of xenobiotic metabolism in liver: an emerging tool for enabling clinical translational research. Clin. Transl. Sci. 2009, 2:228-237.
25. Ishikawa M., Yogita S., Takai S., Komi N., Makuuchi M. A new method for determining cellular ATP content in hepatocytes. Tokushima J. Exp. Med. 1993, 40:119-124.
26. Iwanaga T., Nakakariya M., Yabuuchi H., Maeda T., Tamai I. Involvement of bile salt export pump in flutamide-induced cholestatic hepatitis. Biol. Pharm. Bull. 2007, 30:739-744.
27. Jaiswal A. Nrf2/INrf2 (Keap1) signaling in oxidative stress and cellular protection. Pathways 2010, 12:1-4.
28. Krauss M., Schaller S., Borchers S., Findeisen R., Lippert J., Kuepfer L. Integrating cellular metabolism into a multiscale whole-body model. PLoS Comput. Biol. 2012, 8:1-13.
29. Legendre A., Baudoin R., Alberto G., Paullier P., Naudot M., Bricks T., Brocheton J., Jacques S., Cotton J., Leclerc E. Metabolic characterization of primary rat hepatocytes cultivated in parallel microfluidic biochips. J. Pharm. Sci. 2013, 102:3264-3276.
30. Legendre A., Fleury M.J., Allora I., Naudot M., Bricks T., Jacques S., Leclerc E. Cellular responses of hepatocytes induced by hypothermia: modulation of cytokinesis and drug metabolism related functions. Therap. Hypotherm. Temp. Manage. 2014, 4:32-42.
31. Legendre A., Jacques S., Dumont F., Cotton J., Paullier P., Fleury M.J., Leclerc E. Investigation of the hepatotoxicity of flutamide: pro-survival/apoptotic and necrotic switch in primary rat hepatocytes characterized by metabolic and transcriptomic profiles in microfluidic liver biochips. Toxicol. In Vitro 2014, 28:1075-1087.
32. Lodish H., Berk A., Zipursky S.L., Matsudaira P., Baltimore D., #Darnell J.E. Molecular Cell Biology 2000, W.H. Freeman and Company, #New York, p. 10. fifth ed.
33. Malec V., Gottschald O.R., Li S., Rose F., Seeger W., Hänze J. HIF-1 alpha signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells. Free Radic. Biol. Med. 2010, 48:1626-1635.
34. Mamprin M., Guibert E., Rodriguez J. Glutathione synthesis during the rewarming of rat hepatocytes preserved in the University Of Wisconsin solution. Cryobiology 2010, 43:310-315.
35. Meister A., Anderson M.E. Glutathione. Annu. Rev. Biochem. 1983, 52:711-760.
36. Prot J.M., Aninat C., Griscom L., Razan F., Brochot C., Guguen Guillouzo C., Legallais C., Corlu A., Leclerc E. Improvement of HepG2/C3a cell functions in a microfluidic biochip. Biotechnol. Bioeng. 2011, 108:1704-1715.
37. Schulz M., Schmoldt A., Donn F., Becker H. The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. Eur. J. Clin. Pharmacol. 1988, 34:633-636.
38. Shan X., Chang Y., Lin G. Messenger RNA oxidation is an early event preceding cell death and causes reduced protein expression. FASEB J. 2007, 21:2753-2764.
39. Shet M., Mc Paul M., Fisher C., Stallings N., Estabrook R. Metabolism of the antiandrogenic drug (flutamide) by human CYP1A2. Drug Metab. Dispos. 1997, 25:1298-1303.
40. Sivaraman A., Leach J.K., Townsend S., Iida T., Hogan B.J., Stolz D.B., Fry R., Samson L.D., Tannenbaum S.R., Griffith L.G. A Microscale In Vitro Physiological Model of the Liver: Predictive Screens for Drug Metabolism and Enzyme Induction. Curr. Drug Metab. 2005, 6:569-592.
41. Sjogren E., Lennernas H., Andersson T., Gråsjo J., Bredberg U. The Multiple Depletion Curves Method Provides Accurate Estimates of Intrinsic Clearance (CLint), Maximum Velocity of the Metabolic Reaction (Vmax), and Michaelis Constant (Km): Accuracy and Robustness Evaluated through Experimental Data and Monte Carlo Simulations. Drug Metab. Dispos. 2009, 37:47-58.
42. Wang H.X., Ma X.C., Deng Q.L., Li D. Cytotoxicity of flutamide and 2 hydroflutamide and their effects on CYP1A2 mRNA in primary rat hepatocytes. Acta Pharmacol. Sin. 2002, 23:562-566.
43. Wikswo J., Curtis E., Eagleton Z., Evans B., Kole A., Hofmeister L., Matloff W. Scaling and systems biology for integrating multiple organs-on-a-chip. Lab. Chip 2013, 13:3496.
44. Zhang D. Mechanistic studies of the NRF2-KEAP1 signaling pathway. Drug Metab. Rev. 2006, 38:769-789.
45. Zhang Q., Pi J., Woods C., Andersen M. Phase I to II cross-induction of xenobiotic metabolizing enzymes: a feedforward control mechanism for potential hormetic responses. Toxicol. Appl. Pharmacol. 2009, 237:345-356.
46. Zong W., Thompson C. Necrotic death as a cell fate. Genes Dev. 2006, 20:1-15.